Maplirpacept

Generic Name: Maplirpacept

Drug Type: Biotech

Unique Ingredient Identifier: 44D51T6SZH

Background: Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG.

Clinical Trials

A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China

Phase 1

Completed

Conditions: Multiple Myeloma
Non-Hodgkin Lymphoma

Interventions: Drug: Maplirpacept

First Posted Date: 2023-06-09

Last Posted Date: 2024-11-20

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT05896774

Locations: 🇨🇳
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

and more 2 locations

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

Phase 1

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: maplirpacept (PF-07901801)
Drug: Glofitamab
Drug: Obinutuzumab

First Posted Date: 2023-06-09

Last Posted Date: 2025-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 70

Registration Number: NCT05896163

Locations: 🇦🇺
Epworth Freemasons, Melbourne, Victoria, Australia
🇦🇺
Slade Pharmacy, Richmond, Victoria, Australia
🇮🇱
Sourasky Medical Center, Tel Aviv, Tell Abīb, Israel

and more 22 locations

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab
Drug: Carfilzomib
Drug: Maplirpacept

First Posted Date: 2023-01-09

Last Posted Date: 2025-04-11

Lead Sponsor: Pfizer

Target Recruit Count: 90

Registration Number: NCT05675449

Locations: 🇺🇸
Clinical Research Advisors (Encino Satellite Location), Encino, California, United States
🇺🇸
Clinical Research Advisors (Korea Town Satellite Location), Los Angeles, California, United States
🇺🇸
Clinical Research Advisors (West Hollywood Satellite Location), Los Angeles, California, United States

and more 28 locations

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Maplirpacept
Drug: Tafasitamab
Drug: Lenalidomide

First Posted Date: 2022-11-23

Last Posted Date: 2025-02-13

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT05626322

Locations: 🇺🇸
Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Lifespan Cancer Institute, Providence, Rhode Island, United States

and more 4 locations

A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies

Phase 1

Completed

Conditions: Lymphoma
Multiple Myeloma

Interventions: Drug: maplirpacept (PF-07901801)

First Posted Date: 2022-10-05

Last Posted Date: 2024-11-06

Lead Sponsor: Pfizer

Target Recruit Count: 7

Registration Number: NCT05567887

Locations: 🇯🇵
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi, Japan
🇯🇵
Yamagata University Hospital, Yamagata, Japan
🇯🇵
Japanese Foundation for Cancer Research, Koto, Tokyo, Japan

and more 1 locations

TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2

Recruiting

Conditions: Recurrent ALK Positive Large B-Cell Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent Grade 3b Follicular Lymphoma
Recurrent High Grade B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ontorpacept
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Drug: Maplirpacept
Procedure: Biopsy

First Posted Date: 2022-08-19

Last Posted Date: 2025-02-24

Lead Sponsor: Mayo Clinic

Target Recruit Count: 62

Registration Number: NCT05507541

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Phase 1

Terminated

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Ovarian Neoplasms
Ovarian Carcinoma
Epithelial Ovarian Cancer
Primary Peritoneal Carcinoma

Interventions: Drug: maplirpacept (PF-07901801)
Drug: Pegylated Liposomal Doxorubicin (PLD)

First Posted Date: 2022-03-02

Last Posted Date: 2024-11-19

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT05261490

Locations: 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
🇺🇸
oncology Consultants, P.A., Houston, Texas, United States
🇺🇸
Oklahoma Cancer Specialist and Research Institute. LLC, Tulsa, Oklahoma, United States

and more 12 locations

A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: TTI-622
Drug: Daratumumab Hyaluronidase-fihj

First Posted Date: 2021-12-01

Last Posted Date: 2025-02-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 7

Registration Number: NCT05139225

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 3 locations

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Lymphoma
Multiple Myeloma
Acute Myeloid Leukemia
Diffuse Large B-Cell Lymphoma

Interventions: Drug: Maplirpacept (PF-07901801)
Drug: Anti-CD20 Targeting agent
Drug: Azacitidine
Drug: Carfilzomib
Drug: Venetoclax
Drug: Dexamethasone
Drug: Isatuximab

First Posted Date: 2018-05-21

Last Posted Date: 2023-12-22

Lead Sponsor: Pfizer

Target Recruit Count: 177

Registration Number: NCT03530683

Locations: 🇺🇸
LAC+USC Medical Center, Los Angeles, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Northside Hospital, Atlanta, Georgia, United States

and more 58 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy